CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
A report released Wednesday by the Congressional Budget Office (CBO) revealed that CMS is highly likely to negotiate the price for Novo Nordisk’s obesity therapy Wegovy (semaglutide) in the coming years, according to Stat. Currently, Medicare only covers certain obesity interventions, like bariatric surgery and behavioral counseling by primary care providers; obesity medications are covered only for type 2 diabetes treatment. Also, according to CBO’s report, Medicare cannot sustainably cover AOMs at their current cost of about $1000 to $1300 for a 4-week supply. CBO's prediction comes after Congress introduced the Treat and Reduce Obesity Act (TROA), which would expand Medicare Part D coverage to anti-obesity medication (AOM) indicated for weight loss. CBO also expects the Department of Health and Human Services to select semaglutide for price negotiations under the Inflation Reduction Act (IRA) within the next few years.
Many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack, according to Axios. Experts explained that the insurance health care providers bought for a cyberattack on their organizations may not provide much protection if they're affected by an attack elsewhere, like the recent Change Healthcare attack. They explained that some providers may not have thought to ask for coverage of an attack on a vendor, or did not want to pay the additional cost, resulting in them being underinsured. Conversely, other providers have been unable to afford any cyber insurance coverage due to soaring rates. Overall, some large health systems estimated that they were losing over $100 million per day due to the Change Healthcare attack, but many cyber insurance carriers limit coverage to no more than $5 million for larger systems. As a result, providers are calling for a federal emergency response to help minimize the attack's fallout.
A new report by the CDC showed that the US life expectancy increased for the first time in 2 years, according to Politico. More specifically, people born in the US in 2022 can expect to live 77.5 years, an increase from 76.4 in 2021. Conversely, life expectancy dropped in 2020 and 2021, which experts said was driven by COVID-19 deaths and drug overdoses; the 2021 life expectancy report marked the lowest US life expectancy since 1996. This recent rise in life expectancy comes as overdose deaths leveled out between 2021 and 2022 and COVID-19 dropped to the fourth leading cause of death in the US. Conversely, the overall infant mortality rate increased by 3.1%. Additionally, death rates for 1- to 4-year-olds jumped 12% and 7% for 5- to 14-year-olds. Despite the recent overall life expectancy rate increase, it has not yet recovered to pre-pandemic levels as the life expectancy was 78.8 in 2019.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More